Immunization

The recommendation includes patients 12 years and older traveling to a country where there is a chikungunya outbreak or where there is an elevated risk for US travelers.

Currently, the recommendation is for patients 75 years and older and those aged 60 to 74 years with an increased risk of severe respiratory syncytial virus.

The FDA approved Penmenvy in February 2025 for use in patients aged 10 to 25 years.

The designation addresses the unmet need for prevention of H5N1, which remains a global health risk, and a phase 1 trial of the vaccine was initiated in November 2024.

Texas reports over 480 cases of measles and 2 measles-related deaths, with 1 including an unvaccinated pediatric patient.

Previous research shows herpes zoster is associated with a higher long-term risk of subjective cognitive decline, with increased risk for men who carried APOE ε4.

A HealthDay Harris Poll highlights the most recent feelings patients have towards vaccines amid outbreaks of vaccine-preventable illness and changes at the federal level impacting public health policy.

The approval expands the flexibility of storing the vaccine to protect against smallpox events or mpox outbreaks.

In an era of persistent medical misinformation, addressing vaccine hesitancy has become a critical challenge for health care professionals.

Jean-Venable Goode, BSPharm, PharmD, and Jeff Goad, PharmD, MPH, presented on the most notable vaccine updates from the past year and how they impact pharmacy practice.

Lauren Angelo, PharmD, associate dean for academic affairs at Rosalind Franklin University, explains common misconceptions and myths about vaccines.

Currently, there is no vaccine to prevent chlamydia, but treatment includes regimens of antibiotics, including doxycycline, azithromycin, and levofloxacin.

Lauren Angelo, PharmD, MBA, discussed current vaccination sentiments across the country and how misinformation has contributed to declining rates among US patients.

Kelly Goode, PharmD, BCPS, FAPhA, FCCP, professor in the department of pharmacotherapy and outcomes science at Virginia Commonwealth University, discusses the current landscape of immunization recommendations.

Chichi Ilonzo Momah, PharmD, discussed what pharmacists can be doing to address vaccine hesitancy and the barriers impeding under-resourced communities.

COVID-19 vaccination before a SARS-CoV-2 infection was associated with a 75% reduced likelihood of long COVID symptoms that impact daily functioning among patients between the ages of 5 and 17 years.

IQVIA released a report detailing pharmacists’ authority to administer vaccines in the US as well as adults’ overall vaccination rates by state.

Researchers investigated the acceptability of community pharmacy-led influenza vaccination and patients’ willingness to return for future immunization.

Pharmacy staff members said that VaxCheck was compatible with pharmacy workflow but there were several barriers to its implementation.

Measles is highly contagious, and the Texas Department of State Health Services said that additional cases are likely to occur in Gaines County, which had 57 cases as of February 21, 2025.

The vaccine is the first virus-like particle single-dose vaccine for chikungunya for patients 12 years and older.

The combination includes 2 previously approved vaccines to target the 5 major serogroups of Neisseria meningitidis.

In order to meet national targets, the United States should expand vaccination administration in complementary sites like pharmacies.

Among providers who took part in a recent study, 57% reported increased vaccination rates after implementing a quality improvement initiative.

Investigators note there were no safety signals related to the vaccine candidate, and participants who developed E. coli disease received treatment and care.

More detailed information can be found on the CDC’s website at www.cdc.gov/vaccines.

RBI-4000 is a self-replicating RNA (srRNA) vaccine developed to stimulate virus-neutralizing immune responses to rabies for prophylactic use.

In their exploration of 2 separate respiratory virus seasons, researchers examined the severity of illness for SARS-CoV-2, influenza, and respiratory syncytial virus.

The US government is entrusting mRNA vaccine pioneers Moderna to develop protection for the gradually increasing threat of avian influenza.

A poll conducted by the Global Healthy Living Foundation found 11% of respondents with chronic conditions do not plan to get vaccinated for flu, COVID-19 or RSV.